5.50
price up icon0.46%   0.02
 
loading
전일 마감가:
$5.48
열려 있는:
$5.545
하루 거래량:
7.47M
Relative Volume:
0.27
시가총액:
$2.20B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.5484
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-7.48%
1개월 성능:
+11.66%
6개월 성능:
-26.50%
1년 성능:
-13.58%
1일 변동 폭
Value
$5.45
$5.69
1주일 범위
Value
$5.28
$5.96
52주 변동 폭
Value
$3.79
$12.36

리커젼 파마 Stock (RXRX) Company Profile

Name
명칭
Recursion Pharmaceuticals Inc
Name
전화
(385) 269-0203
Name
주소
41S RIO GRANDE STREET, SALT LAKE CITY
Name
직원
800
Name
트위터
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
RXRX's Discussions on Twitter

RXRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RXRX
Recursion Pharmaceuticals Inc
5.5059 2.40B 64.60M -377.75M -335.64M -1.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
385.60 96.11B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.15 60.40B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
430.86 54.91B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
672.75 41.30B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.29 33.25B 3.81B -644.79M -669.77M -6.24

리커젼 파마 Stock (RXRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-03 재개 Morgan Stanley Equal-Weight
2023-05-22 개시 Morgan Stanley Equal-Weight
2023-03-16 개시 Needham Buy
2022-09-16 개시 KeyBanc Capital Markets Overweight
2022-04-18 다운그레이드 BofA Securities Buy → Neutral
2022-03-04 다운그레이드 SVB Leerink Outperform → Mkt Perform
2021-09-21 개시 Berenberg Buy
2021-05-11 개시 BofA Securities Buy
2021-05-11 개시 Goldman Neutral
2021-05-11 개시 JP Morgan Neutral
2021-05-11 개시 KeyBanc Capital Markets Overweight
2021-05-11 개시 SVB Leerink Outperform
모두보기

리커젼 파마 주식(RXRX)의 최신 뉴스

pulisher
08:47 AM

Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN

08:47 AM
pulisher
06:55 AM

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript - MSN

06:55 AM
pulisher
Aug 06, 2025

Recursion outlines $100M partnership inflows target by end of 2026 as cash runway extends through Q4 2027 - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

Recursion Pharmaceuticals Reports Q2 Loss, Beats Revenue Estimates - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - ca.finance.yahoo.com

Aug 06, 2025
pulisher
Aug 06, 2025

Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Aug 06, 2025
pulisher
Aug 06, 2025

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace

Aug 06, 2025
pulisher
Aug 06, 2025

Recursion Pharmaceuticals shares fall 1.99% premarket after reporting a wider Q2 loss. - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Recursion Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate

Aug 06, 2025
pulisher
Aug 06, 2025

Recursion Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks

Aug 06, 2025
pulisher
Aug 06, 2025

Recursion (RXRX) Q2 Revenue Jumps 33% - AOL.com

Aug 06, 2025
pulisher
Aug 05, 2025

Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Why Recursion Pharmaceuticals Stock Tanked on Tuesday - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion Pharmaceuticals: Strong Financial Position and Strategic Focus Justify Buy Rating - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Strategy and Innovation - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion Pharmaceuticals (RXRX): A Deep Dive into Platform-Driven Value Creation and Strategic Milestone Potential in 2025 - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion Pharmaceuticals sets $100M partnership inflows target by 2026, extends cash runway to Q4 2027 - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Pharma Boom: RXRX Stocks Soar After Latest Innovation - timothysykes.com

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Benzinga

Aug 05, 2025
pulisher
Aug 05, 2025

Earnings call transcript: Recursion Pharmaceuticals Q2 2025 sees revenue beat - Investing.com

Aug 05, 2025
pulisher
Aug 05, 2025

Up 50% in 3 Months, Is This Stock Still a Buy? - AOL.com

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion Pharmaceuticals shares rise 4.31% premarket after reporting revenue of $19.2 million, exceeding expectations. - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion Pharmaceuticals earnings missed by $0.06, revenue topped estimates - Investing.com Australia

Aug 05, 2025
pulisher
Aug 05, 2025

RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

Aug 05, 2025
pulisher
Aug 05, 2025

Recursion Reports Q2 Financial Results, Deploys Advanced Models for Medicine Discovery. - AInvest

Aug 05, 2025
pulisher
Aug 04, 2025

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? - MSN

Aug 04, 2025
pulisher
Aug 04, 2025

Recursion Pharmaceuticals Earnings Preview - 富途牛牛

Aug 04, 2025
pulisher
Aug 04, 2025

Recursion Pharmaceuticals Q2 2025 Earnings: A TechBio Inflection Point? - AInvest

Aug 04, 2025
pulisher
Aug 03, 2025

What catalysts could drive Recursion Pharmaceuticals Inc. stock higher in 2025Maximize portfolio growth with professional advice - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Why is Recursion Pharmaceuticals Inc. stock attracting strong analyst attentionExpert guidance for superior capital growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Recursion Pharmaceuticals Inc. generate profit in a changing economyFree Predictions - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Does Recursion Pharmaceuticals Inc. stock perform well during market downturnsCapitalize on emerging investment opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

2 Beaten-Down Stocks With Incredible Upside Potential - The Motley Fool

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Recursion Pharmaceuticals Inc. stock price move sharplyCapitalize on emerging trends for profits - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Recursion Pharmaceuticals Inc. stockDiscover hidden gems in the stock market - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Recursion Pharmaceuticals Inc. stock expected to show significant growthExplosive earning power - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Recursion Pharmaceuticals Inc. stockHigh-octane gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

Should I hold or sell Recursion Pharmaceuticals Inc. stock in 2025Outstanding growth strategies - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What analysts say about Recursion Pharmaceuticals Inc. stockTremendous return rates - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month - Yahoo Finance

Aug 02, 2025
pulisher
Aug 01, 2025

What are the latest earnings results for Recursion Pharmaceuticals Inc.Market Forecast Alerts Backed By Experts - jammulinksnews.com

Aug 01, 2025

리커젼 파마 (RXRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.30
price down icon 0.43%
$36.80
price down icon 0.82%
$108.59
price down icon 2.21%
$27.91
price down icon 2.14%
$113.33
price up icon 1.83%
biotechnology ONC
$294.82
price down icon 1.17%
자본화:     |  볼륨(24시간):